Professor says the differing results on vaccine don’t change anything as manufacturer suggests 76% primary efficacy following concerns in US
Pharmaceutical company AstraZeneca has released additional data that it said confirms the efficacy of its Covid-19 vaccine after questions about interim clinical trial results were raised in the US by an independent agency. But the additional data suggests the vaccine is slightly – but not significantly – less effective than the interim results suggested.
Interim results released by AstraZeneca on Monday from the phase-3 clinical trial of more than 32,000 people found the vaccine was 79% effective against symptomatic disease and 100% effective against severe disease and death. But soon after the results were published, the Data and Safety Monitoring Board in the US said it was concerned AstraZeneca may have provided “outdated information” from the trial, which gave “an incomplete view” of the results.
